Navigating the Complexities of Contraceptive Care

Angeline Ti, MD, MPH
Santina Wheat, MD, MPH, FAAFP

ACTIVITY DISCLAIMER

The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.

This live CME session is supported in part by an educational grant from Merck.
DISCLOSURE

It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.

All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.

The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Angeline Ti, MD, MPH

Assistant Professor, Department of Gynecology and Obstetrics, Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia

Dr. Ti earned her Master of Public Health from Johns Hopkins Bloomberg School of Public Health, and is a graduate of the University of Michigan Medical School in Ann Arbor, Michigan. She completed her residency in Family and Community Medicine and a fellowship in Family Planning at the University of California, San Francisco, conducting research on the family planning values and preferences of incarcerated girls. Dr. Ti also completed a 2-year research position in the Division of Reproductive Health at the Centers for Disease Control and Prevention (CDC), working on the CDC contraception guidance. She is now faculty in the Division of Family Planning, and is the medical director of the Title X clinic at Grady Memorial Hospital. She currently provides primary care, transgender care, and family planning care. She also serves on the Georgia AFP Public Health Committee and the Georgia Department of Public Health Maternal Mortality Review Committee Action Committee.
Santina Wheat, MD, MPH, FAAFP

Assistant Professor, Department of Family and Community Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Program Director, Northwestern McGaw Family Medicine Residency at Humboldt Park, Chicago, Illinois; Physician, Erie Family Health Centers, Chicago, Illinois

Dr. Wheat earned her medical degree from the University of Illinois College of Medicine at Chicago, and she earned her Master of Public Health (MPH) degree at the University of Illinois at Chicago School of Public Health. She completed a residency in family medicine at Northwestern McGaw Family Medicine Residency at Humboldt Park in Chicago, Illinois. Dr. Wheat has a strong interest in reproductive health and social determinants of health, and she works with a largely Spanish-speaking patient population at a federally qualified health center (FQHC) in Chicago. She provides full primary care to patients living with HIV/AIDS and hepatitis C. Dr. Wheat is the program director for the Northwestern McGaw Family Medicine Residency. She runs an outpatient procedure clinic with the residents in her program and is part of the maternity care team.

Learning Objectives

1. Consider screening for pregnancy intendedness and offering preconception and/or contraception counseling in the primary care setting for all patients at risk of unintended pregnancy.

2. Assess the special contraceptive needs for women with chronic diseases, for women who are planning to have bariatric surgery, and for trans-men at risk of undesired pregnancy.

3. Counsel patients on the appropriate use and access to emergency contraception, including advanced provision prescription.
Associated Sessions

• (PBL) Navigating the Complexities of Contraceptive Care

Audience Engagement System
Pregnancy in the US

Contraception use during month of conception

- Intended, 55%
- Unintended, 45%
- Nonuse, 54%
- Inconsistent use, 41%
- Consistent use, 5%


Increasing rates of chronic disease among reproductive-aged women

<table>
<thead>
<tr>
<th>Age groups (years)</th>
<th>Depression</th>
<th>Diabetes</th>
<th>Hypertension</th>
<th>Overweight/Obesity</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>19%</td>
<td>1.0%</td>
<td>5.0%</td>
<td>33%</td>
</tr>
<tr>
<td>25-34</td>
<td>23%</td>
<td>2.4%</td>
<td>9.2%</td>
<td>57%</td>
</tr>
<tr>
<td>35-44</td>
<td>23%</td>
<td>5.3%</td>
<td>17%</td>
<td>62%</td>
</tr>
</tbody>
</table>

Why does this matter?

Preventable Pregnancy Deaths in America Are ‘Alarmingly’ High

The New York Times

KFF

New Title X Regulations: Implications for Women and Family...

New Title X Regulations: Implications for Women and Family Planning Providers

Laurie Sobel, Alina Salganicoff, and Britni Frederiksen

Published: Mar 08, 2019

So where do we start?
Amy

24 year old patient comes to the office for a same-day appointment with new UTI symptoms.

AES Polling Question 1

• How frequently do you ask patients about their pregnancy intentions?
  – A) I ask nearly all patients
  – B) I ask nearly all female patients
  – C) I sometimes ask, depending on the visit type
  – D) I never or rarely ask
  – E) What do you mean, “pregnancy intentions”? 
Screening for pregnancy intention

• One Key Question
• Intention-oriented vs service-oriented
  – “Do you want to get pregnant soon?”
  – “Can we help you today with birth control or pregnancy planning?”

“Power to Decide, One Key Question”: https://powertodecide.org/one-key-question


Screening for pregnancy intention

• Starts a conversation
• Proactively identify need for contraception or pre-pregnancy planning
• Will change as individual circumstances change
Alice

- 36 year old patient with hypertension comes for a routine follow-up visit and a med refill.

Alice

- BP 145/90, BMI 32

- Not planning pregnancy and open to discussing contraception
AES Polling Question 2

• What contraception is safe for Alice?
  – A) Non-hormonal methods
  – B) Progestin-only methods
  – C) Estrogen-containing methods
  – D) A & B
  – E) All of the above

CDC contraception guidance

• US Medical Eligibility Criteria for Contraceptive Use (MEC)
  – Safe use of contraceptive methods by patients with certain characteristics or medical conditions
  – More than 1800 recommendations for over 120 medical conditions and sub-conditions
US MEC

Summary Chart of U.S. Medical Eligibility Criteria

Risk Level

1  Method can be used without restriction
2  Advantages generally outweigh theoretical or proven risk
3  Theoretical or proven risks usually outweigh the advantages
4  Unacceptable health risk (method not to be used)


Hypertension

b. Elevated blood pressure levels (properly taken measurements)

i. Systolic 140–159 mm Hg or diastolic 90–99 mm Hg

†Clarifications

For all categories of hypertension, classifications are based on the assumption that no other risk factors exist for cardiovascular disease. When multiple risk factors do exist, risk for cardiovascular disease might increase substantially. A single reading of blood pressure level is not sufficient to classify a woman as hypertensive.
Look at the US MEC

- Case a. BMI ≥ 30 kg/m²
- Case b. Menopause <16 years and BMI ≥ 30 kg/m²

Evidence

Obesity a. BMI ≥ 30 kg/m²

- Co-UD 1
- LNG-IUD 1
- Implants 1
- DMPPA 1
- POP 1
- CCHCs 2

References:

1.• Obesity among women is more common than among men. Women who use COCs are more likely than obese women who do not use COCs to experience VTE. Research examining the interaction between COCs and BMI on VTE risk is limited, particularly for women in the highest BMI categories (BMI ≥ 35 kg/m²). Although the absolute risk for VTE in otherwise healthy women of reproductive age is small, obese women are at 2-3 times higher risk for VTE than normal weight women regardless of COC use. Limited evidence suggests that obese women who use COCs do not have a higher risk for acute mesenteric or other obesity-related disorders or events than do obese nonusers. Limited evidence suggests that effectiveness of some COC formulations might decrease with increasing BMI, however the observed reductions in effectiveness are minimal and evidence is conflicting. Efficacy of the patch might be reduced in women ≥ 60 kg. Limited evidence suggests that obesity is more likely to gain weight during COC or vaginal ring use than normal weight or overweight women.
Anna

• 31 year old patient who is scheduled for bariatric surgery next month. She was referred to primary care for contraception.

Increased maternal risks in pregnancy

• Breast, endometrial, or ovarian cancer
• Complicated valvular heart disease
• Cystic fibrosis
• Diabetes
• Epilepsy
• Hypertension (>160/100)
• History of bariatric surgery in last 2 years
• HIV (uncontrolled)
• Ischemic heart disease
• Hepatoma
• Peripartum cardiomyopathy
• Severe cirrhosis
• Sickle cell disease
• Solid organ transplantation with in the last 2 years
• Thrombogenic mutations

Bariatric surgery and reproductive health

Rapid weight loss following surgery may lead to increased fertility

Recommendations to delay pregnancy for 1-2 years after surgery


AES Polling Question 3

• What contraception can Anna use?
  – A) Any method
  – B) Any non-oral method
  – C) Only the most effective methods- LARC or sterilization
  – D) It depends on the type of surgery
Anna

• Anna has been struggling with infertility for many years and tells you that she actually plans on trying to get pregnant as soon as she’s recovered from her surgery.
Pregnancy risks after bariatric surgery

- Misdiagnosing pregnancy vs surgical complications
- Continued obesity
- Micronutrient deficiencies
- Inconclusive evidence for patient-oriented outcomes


Shared decision-making

- Patient values, preferences, and situation
- Medical evidence, risks and benefits

Individualized decision
Andy

• 24 year old patient, assigned female at birth who is about to start gender-affirming testosterone.
• Not interested in pregnancy

AES Polling Question 4

• Which contraceptive methods are safe for Andy?
  – A) All of them
  – B) Any method without estrogen
  – C) Any method without hormones
Contraception & testosterone

• Amenorrhea ≠ anovulation
  – Category D in pregnancy

• Method-specific considerations:
  – Estrogen is safe when taken with testosterone, but may counter its effects
  – Testosterone can cause vaginal dryness


Andy

• After discussion options, Andy would like to start depo-medroxyprogesterone (DMPA). Last menstrual period was 2 weeks ago, and last unprotected vaginal sex was 3 days ago.
CDC contraception guidance

- US Selected Practice Recommendations for Contraceptive Use (SPR)
  - Guidance for common contraceptive management topics such as:
    - How to be reasonably certain a patient is not pregnant
    - When to start contraception
    - Medically indicated exams and tests
    - Follow-up and management of certain problems


CDC pregnancy checklist

- You can be reasonably certain Andy is not pregnant if any of the criteria apply:
  - Is ≤ 7 days after the start of normal menses
  - Has not had sex since last menses
  - Has been correctly using contraception
  - Is ≤ 7 days after spontaneous or induced abortion
  - Is within 4 weeks postpartum
  - Meets criteria for lactational amenorrhea

What about that unprotected sex?

Emergency Contraception (EC)

- Indications:
  - Unprotected sex
  - Concern for contraceptive failure
  - Incorrect use
  - Sexual assault
- Timing: within 5 days (120 hours)

WHO. Emergency Contraception. 2 Feb 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/emergency-contraception
Available methods of EC

<table>
<thead>
<tr>
<th></th>
<th>Copper IUD</th>
<th>Ulipristal Acetate Pills</th>
<th>Progestin Pills</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is it?</td>
<td>Emergency contraception (EC) is birth control you can use after unprotected sex.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>What does it do?</td>
<td><strong>EC prevents</strong> a pregnancy after unprotected sex. <strong>EC does not</strong> end a pregnancy and will <strong>not</strong> work if you are pregnant.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td>Copper</td>
<td>Ulipristal acetate</td>
<td>Levonorgestrel</td>
</tr>
</tbody>
</table>

Additional considerations for EC

- **Failure (pregnancy) rates:**
  - LNG EC: 1.2-2.1%
    - Increased with higher BMI, >72 hours since unprotected sex
  - UPA EC: 1.2%
  - Cu IUD: <1%
- **Combined oral contraceptives (Yuzpe method)**

WHO. Emergency Contraception. 2 Feb 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/emergency-contraception
AES Polling Question 5

- Andy doesn’t want a pelvic exam so chooses EC pills. Can Andy also start DMPA today?
  - A) Yes
  - B) No
  - C) Depends on what kind of EC he chooses

Contraception after EC

- Copper IUD: none needed!
- Levonorgestrel (LNG) EC: can start same day as EC
- Ulipristal acetate EC: starting hormonal contraception within 5 days may decrease effectiveness of EC
- Pregnancy test in 3 weeks if not withdrawal bleed

Shared decision-making

Patient values, preferences, and situation
Medical evidence, risks and benefits

Individualized decision

Increasing access to EC

• Advanced provision leads to increased use and more timely use
• One form of LNG EC is available over the counter for ~ $50/pill
  – Availability to other brands varies by state, insurance, age

Practice recommendations

• Screen patients regularly for pregnancy intention: intention-oriented vs service-oriented

• Utilize evidence-based guidance to provide contraception safely to all patients, including those with chronic medical conditions

• Assess the need for emergency contraception and recognize best practices for implementation

Billing & Coding

ICD 10 Codes:
• Z30.011 Initial, contraceptive pills
• Z30.012 EC prescription
• Z30.013 Initial, Injection
• Z30.014 Initial, IUC
• Z30.015 Initial, Ring
• Z30.016 Initial, Patch
• Z30.017 Initial, Implant
• Z30.41 surveillance, contraceptive pills
• Z30.42 Surveillance, Injection
• Z30.43 Surveillance, IUC
• Z30.44 Surveillance, Ring
• Z30.45 Surveillance, Patch
• Z30.46 Surveillance, Implant
Billing & Coding

Procedure (CPT) Codes:

- **58300 Insertion of IUD**
  - Z30.430 encounter for insertion of IUC
  - J7298 Mirena, J7297 Liletta, J7300 Paragard, J7301 Skyla,
- **58301 IUD removal**
  - Z30.432 encounter for removal of IUC
- **58300 & 58301 for IUD removal & reinsertion**
  - Z30.433 & relevant J code

Billing & Coding

CPT Codes:

- **11981 Insertion Implant**
  - Z30.017 encounter for insertion of Implant
  - J7307 Nexplanon
- **11982 Removal Implant**
  - Z30.46 encounter for surveillance of Implant
  - J7307
- **11983 Removal & Reinsertion Implant**
  - Z30.46
Billing & Coding

Other helpful codes:
• J2000 Lidocaine

• A4550 Surgical Tray

• 53 modifier can be used for attempted, but unsuccessful, IUD insertions

Some useful resources

• Bedsider: https://providers.bedsider.org/
• CDC contraception guidance: https://www.cdc.gov/reproductivehealth/contraception/contraception_guidance.htm
• Reproductive Health Access Project: https://www.reproductiveaccess.org/
• UCSF transgender guidelines: https://transcare.ucsf.edu/guidelines
Contact us with questions!

Angeline Ti  ati@emory.edu
Santina Wheat  tina.wheat@gmail.com

Questions